Last reviewed · How we verify
NCT05384353
In Vivo PET of Synaptic Density in Cognitive Disorders
trial testing [18F]-SynVesT-1 in Alzheimer Disease in 134 participants. Completed in 4 June 2025.
28 May 2025
Quick facts
| Lead sponsor | Universitaire Ziekenhuizen KU Leuven |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 134 |
| Start date | 11 April 2022 |
| Primary completion | 28 May 2025 |
| Estimated completion | 4 June 2025 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- [18F]-SynVesT-1
Conditions studied
- Alzheimer Disease — all drugs for Alzheimer Disease →
- Frontotemporal Degeneration — all drugs for Frontotemporal Degeneration →
- Dementia With Lewy Bodies — all drugs for Dementia With Lewy Bodies →
- Psychiatric Disorder — all drugs for Psychiatric Disorder →
Sponsor
Universitaire Ziekenhuizen KU Leuven — full company profile →
Who can join
18 and older, any sex, with Alzheimer Disease or Frontotemporal Degeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will compare the discriminative power of \[18F\]-SynVesT-1 PET and the standard-of-care \[18F\]-FDG PET in different cognitive disorders (Alzheimer's disease, Frontotemporal degeneration, dementia with Lewy bodies and late-life psychiatric disorders). Moreover, changes in \[18F\]-SynVesT-1 PET will be evaluated as well as their correlation with specific symptomatology.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
In vivo PET of synaptic density as potential diagnostic marker for cognitive disorders: prospective comparison with current imaging markers for neuronal dysfunction and relation to symptomatology - study protocol.
Vanderlinden G, Carron C, Vandenberghe R, Vandenbulcke M, et al · · 2024 · cited 3× · PMID 38347458 · DOI 10.1186/s12880-024-01224-5 -
EXPRESS: Quantification of 18F-SynVesT-1 binding in healthy aging and head-to-head comparison with 11C-UCB-J.
Vanderlinden G, Carron C, Van Opstal J, Cohilis M, et al · · 2026 · PMID 42219995 · DOI 10.1177/0271678x261454164
Verify or expand the search:
- PubMed search for NCT05384353
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alzheimer Disease
Currently open trials in the same condition.
- NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
- NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
- NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
- NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
- NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting
Other Universitaire Ziekenhuizen KU Leuven trials
Trials by the same sponsor.
- NCT06831955 — LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer · Phase 2 · recruiting
- NCT07356505 — Efficacy and Safety of Micra AV2 Transcatheter Pacing System · NA · recruiting
- NCT07286968 — Gastro-Intestinal Digestion and Physiology After Bariatric Surgery · recruiting
- NCT06962137 — Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer · Phase 2 · recruiting
- NCT07270536 — Accelerated Pacing and Cardiac Filling Pressures During Exercise in Patients With Heart Failure With Preserved Ejection · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05384353 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universitaire Ziekenhuizen KU Leuven
- Last refreshed: 8 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05384353.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing